We are live on ! Find out more
ALDR

Alder Biopharmaceuticals
ALDR

Delisted

ALDR was delisted on the 21st of October, 2019.

Back to rankings

145 hedge funds and large institutions have $1.35B invested in Alder Biopharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 64 increasing their positions, 31 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

264% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 11

106% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 31

24% more funds holding

Funds holding: 117 → 145 (+28)

23% more capital invested

Capital invested by funds: $1.1B → $1.35B (+$247M)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

61% less call options, than puts

Call options by funds: $3.82M | Put options by funds: $9.72M

Holders
145
Holders Change
+28
Holders Change %
+23.93%
% of All Funds
3.87%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.19%
New
40
Increased
64
Reduced
31
Closed
11
Calls
$3.82M
Puts
$9.72M
Net Calls
-$5.9M
Net Calls Change
+$1.91M

Top Buyers

1
Wellington Management Group
Wellington Management Group
Massachusetts
+$33.1M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$24.2M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$22.7M
4
Marshall Wace
Marshall Wace
United Kingdom
+$20.8M
5
SIG
Senator Investment Group
New York
+$19M

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$29.9M
2
SAM
Sectoral Asset Management
Quebec, Canada
-$20.7M
3
EAM
EverPoint Asset Management
Connecticut
-$11.5M
4
Citadel Advisors
Citadel Advisors
Florida
-$7.48M
5
AllianceBernstein
AllianceBernstein
Tennessee
-$6.07M
Name Holding Trade Value Shares
Change 		Change in
Stake
Brown Advisory
26
Brown Advisory
Maryland
$10.7M +$1.24M +45,816 +12%
PA
27
Perceptive Advisors
New York
$9.99M +$676K +25,000 +7%
Asset Management One
28
Asset Management One
Japan
$9.38M -$544K -20,099 -5%
EAM
29
EverPoint Asset Management
Connecticut
$8.74M -$11.5M -425,000 -55%
JP Morgan Chase
30
JP Morgan Chase
New York
$8.64M -$99K -3,661 -1%
SAM
31
Senzar Asset Management
New York
$8.47M -$4.72M -174,500 -34%
Geode Capital Management
32
Geode Capital Management
Massachusetts
$8.15M +$3.98M +147,236 +82%
Axa
33
Axa
France
$7.16M +$905K +33,441 +13%
BA
34
BlackRock Advisors
Delaware
$6.91M +$780K +28,812 +12%
Franklin Resources
35
Franklin Resources
California
$6.24M +$6.76M +250,000 New
EMFAT
36
Emerald Mutual Fund Advisers Trust
Pennsylvania
$5.99M +$6.49M +239,889 New
EA
37
Emerald Advisers
Pennsylvania
$5.9M +$6.39M +236,193 New
Ameriprise
38
Ameriprise
Minnesota
$5.83M +$490K +18,103 +8%
State of Wisconsin Investment Board
39
State of Wisconsin Investment Board
Wisconsin
$5.62M +$6.09M +225,000 New
Norges Bank
40
Norges Bank
Norway
$5.5M -$2.38M -88,000 -29%
BBA
41
Baker Bros. Advisors
New York
$5.43M +$5.88M +217,328 New
Macquarie Group
42
Macquarie Group
Australia
$5.02M +$3.54M +130,900 +187%
Fiera Capital (Canada)
43
Fiera Capital (Canada)
Quebec, Canada
$5M +$5.42M +200,362 New
Bank of New York Mellon
44
Bank of New York Mellon
New York
$4.94M +$2.47M +91,328 +86%
NLVP
45
New Leaf Venture Partners
New York
$4.76M -$1.54M -57,000 -23%
BIM
46
BlackRock Investment Management
Delaware
$4.67M +$2.54M +93,980 +101%
CS
47
Credit Suisse
Switzerland
$4.67M +$7.55K +279 +0.1%
RSCM
48
Rock Springs Capital Management
Maryland
$4.51M +$2.25M +83,000 +85%
Deutsche Bank
49
Deutsche Bank
Germany
$4.46M -$3.53M -130,452 -42%
HCMT
50
Highland Capital Management (Texas)
Texas
$4.41M +$1.4M +51,700 +41%
1
2
3 4 5

ALDR Hedge Fund Activity: Q2 2016 in Review

145 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Alder Biopharmaceuticals (ALDR) for Q2 2016, worth a combined $1.35B — up 23% from $1.1B a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new ALDR positions and 11 closed out — a net gain of 29 holders — while 64 added to existing stakes and 31 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $33.1M. The largest seller was Point72 Asset Management, cutting an estimated $29.9M.

  • 145 institutional investors held Alder Biopharmaceuticals (ALDR) as of Q2 2016, up from 117 in Q1 2016.
  • Funds reported $1.35B of Alder Biopharmaceuticals stock for Q2 2016, up 23% quarter-over-quarter.
  • 40 funds opened new Alder Biopharmaceuticals positions in Q2 2016 and 11 closed out, a net change of +29 holders.
  • The largest Alder Biopharmaceuticals buyer in Q2 2016 was Wellington Management Group, an estimated $33.1M added.
  • The largest Alder Biopharmaceuticals seller in Q2 2016 was Point72 Asset Management, an estimated $29.9M sold.

Based on aggregated 13F filings for Q2 2016.